Psoriasis

>

Latest News

FDA Approves Guselkumab for Pediatric Plaque Psoriasis and Active Psoriatic Arthritis / image credit:©Calin/AdobeStock
FDA Approves Guselkumab for Pediatric Plaque Psoriasis and Active Psoriatic Arthritis

September 30th 2025

The FDA has approved guselkumab for children aged 6 years and older with moderate to severe plaque psoriasis or active psoriatic arthritis, making it the first IL-23 inhibitor authorized for pediatric use.

Investigational Oral IL-23 Receptor Antagonist Improves Skin Clearance in Psoriasis: Daily Dose / image credit: ©New Africa/AdobeStock
Investigational Oral IL-23 Receptor Antagonist Improves Skin Clearance in Psoriasis: Daily Dose

August 25th 2025

Investigational Oral IL-23 Receptor Antagonist Icotrokinra Improves Skin Clearance in Psoriasis in Phase 3 Study / image credit Robert Bissonnette, MD, International Eczema Council
Investigational Oral IL-23 Receptor Antagonist Icotrokinra Improves Skin Clearance in Psoriasis in Phase 3 Study

August 11th 2025

Roflumilast Foam 0.3% Update: Pivotal Phase 3 Trial Outcomes Published in JAMA Dermatology, Arcutis Announces / image courtesy of Arcutis
Roflumilast Foam 0.3% Update: Pivotal Phase 3 Trial Outcomes Published in JAMA Dermatology, Arcutis Announces

May 8th 2025

April Issue of Patient Care Digital Edition is Now Live
April Issue of Patient Care Digital Edition is Now Live

March 27th 2025

More News

Tildrakizumab Shows Efficacy for Nail Psoriasis in Phase 3b Trial

Tildrakizumab Shows Efficacy for Nail Psoriasis in Phase 3b Trial

Patient Care Editorial Staff
March 7th 2025

The findings highlight the potential of the interleukin-23 inhibitor to address a notoriously difficult-to-treat manifestation of psoriasis.

New Study Suggests Patient Benefit Index Complements Traditional Psoriasis Outcome Measures / image credit ©InfiniteStudio/AdobeStock

New Study Suggests Patient Benefit Index Complements Traditional Psoriasis Outcome Measures

Sydney Jennings
January 20th 2025

Findings showed that improved skin clearance and reduced anxiety and depression significantly influenced perceived patient benefit.

© 2025 MJH Life Sciences

All rights reserved.